Evidence map›Paper›PMID 35904695›Full record

SynthesisCurrent HIV/AIDS reports2022

Examining the Use of HIV Self-Testing to Support PrEP Delivery: a Systematic Literature Review.

Catherine Kiptinness, Alexandra P Kuo, Adriana M Reedy, Cheryl C Johnson, Kenneth Ngure, Anjuli D Wagner, Katrina F Ortblad

Abstract readSystematic Review
In one paragraph

Synthesis in Current HIV/AIDS reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. HIV-1 testing in the context of expanding PrEP modalities.Journal of the International AIDS Society · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Catherine KiptinnessDepartment of Public and Global Health, University of Nairobi, Nairobi, Kenya.
Alexandra P KuoDepartment of Pharmacy, University of Washington, Seattle, WA, 98195, USA.
Adriana M ReedyPublic Health Sciences Division, Fred Hutchinson Cancer Center, 1100 Fairview Ave N, Seattle, WA, 98109, USA.
Cheryl C JohnsonGlobal HIV, Hepatitis and STI Programmes, World Health Organization, Geneva, Switzerland.
Kenneth NgureDepartment of Pharmacy, University of Washington, Seattle, WA, 98195, USA.
Anjuli D WagnerDepartment of Pharmacy, University of Washington, Seattle, WA, 98195, USA.
Katrina F OrtbladPublic Health Sciences Division, Fred Hutchinson Cancer Center, 1100 Fairview Ave N, Seattle, WA, 98109, USA. kortblad@fredhutch.org.

Funding

Peer PrEP referral + HIV self-test for PrEP initiation among young Kenyan womenR00MH121166 · NIMH · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ORTBLAD, KATRINA FRANCES · 2021 to 2024
$866k
Testing implementation strategies to improve delivery of PrEP for pregnant and postpartum women in KenyaK01MH121124 · NIMH · UNIVERSITY OF WASHINGTON · PI WAGNER, ANJULI DAWN · 2019 to 2023
$835k
Pharmacy delivery to expand the reach of PrEP in KenyaR34MH120106 · NIMH · UNIVERSITY OF WASHINGTON · PI ORTBLAD, KATRINA FRANCES · 2019 to 2020
$605k
Peer PrEP referral + HIV self-test for PrEP initiation among young Kenyan womenK99MH121166 · NIMH · UNIVERSITY OF WASHINGTON · PI ORTBLAD, KATRINA FRANCES · 2020 to 2020
$122k
NIMH NIH HHS K01 MH121124NIMH NIH HHS K99 MH121166NIMH NIH HHS R00 MH121166NIMH NIH HHS R34 MH120106World Health Organization 001
6 · The paper itself

Abstract

purpose of reviewHIV self-testing (HIVST) has the potential to expand access to and uptake of HIV pre-exposure prophylaxis (PrEP) delivery. We conducted a systematic literature review to understand the evidence on HIVST use for PrEP delivery. RECENT

findingsAfter screening 1055 records, we included eight: three randomized trials and five values and preferences studies. None measured PrEP initiation. Most studies occurred in Sub-Saharan Africa (7/8) and included different populations. One trial found that HIVST use between quarterly clinic visits as part of an adherence package with biofeedback slightly increased adherence; the other two trials found that HIVST use between or in lieu of quarterly clinic visits had no significant or non-inferior effects on adherence. HIVST to support PrEP delivery was acceptable, feasible, and preferred. HIVST use for PrEP continuation largely resulted in similar outcomes to standard-of-care delivery and was perceived acceptable and feasible. Further research is needed to optimize HIVST use within PrEP programming.

Indexed as

HIV InfectionsPre-Exposure ProphylaxisHIV TestingHumansMass ScreeningSelf-TestingHIV preventionHIV self-testingImplementation sciencePrEP deliverySub-Saharan AfricaSystematic literature review

Identifiers

PMID35904695
PMCPMC9334974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.